PubMed COVID-19 Clinical Care

CONCLUSIONS: This original QPSSE was found to be a reliable and valid tool for AIS treated conservatively with PSSE and for the patients' clinicians.

Host factors that define the cellular tropism of SARS-CoV-2 beyond the cognate ACE2 receptor are poorly defined. From a screen of human airway derived cell lines that express varying levels of ACE2/TMPRSS2, we found a subset that express comparably

INTRODUCTION: Because prior immune checkpoint inhibitor (ICI) therapy in cancer patients presenting with COVID-19 may affect outcomes, we investigated the beta-coronavirus, murine hepatitis virus (MHV)-1, in a lethal pneumonia model in the absence

Porcine deltacoronavirus (PDCoV) is a novel enteric coronavirus that can cause vomiting, watery diarrhea in pigs and the death of piglets. The open reading frame (ORF) 5 is one of the accessory genes in PDCoV genome and encodes an accessory protein

The onset of the SARS-CoV-2 virus led to the appearance of a devastating pandemic, which once again demonstrated the practical importance of virology [...].

Ameloblastoma is a benign epithelial tumor that has aggressive, destructive and unlimited growth potential, having the capacity for recurrence and malignant transformation. Regarding the symptoms and clinical signs, the presentation of ameloblastoma

CONCLUSION: Dural arteriovenous fistula can develop after CVST in association with COVID-19 vaccination.

The COVID-19 pandemic has triggered several changes in countries' health purchasing arrangements to accompany the adjustments in service delivery in order to meet the urgent and additional demands for COVID-19 related services. However, evidence on

This paper examines the effectiveness of non-pharmaceutical measures adopted by governments to control the evolution of the COVID-19 pandemic. Using a Panel VAR model for the OECD countries, we test for Granger causality between the 7-day cumulative

We evaluated cellular immune responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in an immunized population based on HLA-E-restricted CD8^(+) T cell epitope identification. HLA-E-restricted SARS-CoV-2 CD8^(+) T